About terns pharmaceuticals inc - TERN
Terns Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, or NASH, and other chronic liver diseases. The firm's pipeline includes clinical stage development programs, including a FXR agonist, a VAP-1 inhibitor, a THR-ß agonist, and a preclinical GLP-1 receptor agonist program. The company was founded by Randall L. Halcomb, Martijn Fenaux, and Weidong Zhong in 2017 and is headquartered in Foster City, CA.
TERN At a Glance
Terns Pharmaceuticals, Inc.
1065 East Hillsdale Boulevard
Foster City, California 94404
| Phone | 1-650-525-5535 | Revenue | 0.00 | |
| Industry | Biotechnology | Net Income | -88,853,000.00 | |
| Sector | Health Technology | Employees | 59 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
TERN Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 1.396 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.828 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.016 |
TERN Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,505,983.051 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
TERN Liquidity
| Current Ratio | 23.138 |
| Quick Ratio | 23.138 |
| Cash Ratio | 22.886 |
TERN Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -28.098 |
| Return on Equity | -29.557 |
| Return on Total Capital | -25.59 |
| Return on Invested Capital | -29.512 |
TERN Capital Structure
| Total Debt to Total Equity | 0.389 |
| Total Debt to Total Capital | 0.388 |
| Total Debt to Total Assets | 0.37 |
| Long-Term Debt to Equity | 0.266 |
| Long-Term Debt to Total Capital | 0.265 |